

Steven P. Treon, MD, PhD

Director, Bing Center for Waldenström's Macroglobulinemia
Senior Physician, Dana-Farber Cancer Institute
Associate Professor of Medicine, Harvard Medical School

Phone: 617-632-6285

Email: steven_treon@dfci.harvard.edu

Assistant: Chris Patterson

Phone: 617-632-3823

Email: Christopher_Patterson@dfci.harvard.edu

Dr. Steven Treon is the Director of the Bing Center for Waldenström's Macroglobulinemia and a Senior Physician at the Dana-Farber Cancer Institute and Brigham and Women's Hospital, in Boston, Massachusetts. He is also an Associate Professor of Medicine at Harvard Medical School, and is the Chair of the Waldenström's Macroglobulinemia Clinical Trials Group.

Dr. Treon earned his MD and PhD degrees with honors from the Boston University School of Medicine. He completed an internship in medicine and a residency in internal medicine at Boston University Medical Center, a clinical fellowship in Hematology and Medical Oncology at the Massachusetts General Hospital, and a Research Fellowship at Dana-Farber Cancer Institute and Harvard Medical School.

Dr. Treon's main research interests focus on understanding the genetic basis and pathogenesis of Waldenström's Macroglobulinemia (WM) and the development of therapeutics for this malignancy. Using whole-genome sequencing, his laboratory first defined the genomic basis for WM that included the identification of highly prevalent activating mutations in MYD88 and CXCR4. Dr. Treon's laboratory also identified that Bruton's Tyrosine Kinase (BTK) was a downstream target of mutated MYD88. This finding enabled a clinical trial led by Dr. Treon that received the first ever breakthrough designation by the FDA, and subsequent fast track approval of the BTK inhibitor ibrutinib by the U.S. FDA and the European Medicines Agency. Dr. Treon's work also showed that the mutation status of MYD88 and CXCR4 could be used as predictive markers for ibrutinib treatment response in WM. His current efforts are focused on defining the transcriptome and epigenome of WM, and the development of inhibitors that target MYD88 and CXCR4 signaling in WM.

Dr. Treon has served as the principal organizing chair of the International Workshops on WM. He is an active educator, and has taught broad audiences across the globe on the genetic basis, biology and therapy of WM. Dr. Treon has also published extensively on topics in WM and related disorders, with over 250 peer-reviewed original reports, authoritative reviews, editorials, and chapters included in many high-impact journals and textbooks. Dr. Treon has been honored with research and academic awards from various national and international medical foundations and institutions, including the Robert A. Kyle Award for Waldenström's Macroglobulinemia, the Jan Gosta

Waldenstrom Lifetime Achievement Award, the Laurie Strauss Leukemia Foundation Outstanding Cancer Investigator Award, the "One-Hundred Award by the Massachusetts General Hospital. Dr. Treon has also been designated as one of "America's Top Doctors" by U.S. News and World Report.